Skip to main content
SpringerLink
Log in

DLI Induced by Nonmolecular Target Antineoplastic Drugs: What Are the Characteristics of DLI in Nonmolecular Target Antineoplastic Drugs?

  • Chapter
  • First Online:
Drug-Induced Lung Injury

Abstract

All cytotoxic antineoplastic drugs can potentially cause drug-induced lung injury (DLI), although the frequency and type of DLI vary and the time of DLI onset depends on the drug. Risk factors for DLI include longer treatment time, poor performance status, heavy smoking history, and underlying lung comorbidities. The risk of DLI caused by cytotoxic antineoplastic drugs increases when they are combined with other antineoplastic drugs and irradiation. Therefore, all patients treated with cytotoxic antineoplastic drugs are at risk of DLI. During treatment with cytotoxic antineoplastic drugs, patient oxygen saturation should be monitored by oximetry. When respiratory symptoms occur, it is important to suspect DLI and to perform computed tomography immediately to diagnose DLI.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rudders RA, Hensley GT. Bleomycin pulmonary toxicity. Chest. 1973;63(4):627–8.

    Article  CAS  PubMed  Google Scholar 

  2. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic drugs. Ann Oncol. 2006;17(3):372–9.

    Article  CAS  PubMed  Google Scholar 

  3. Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63–74.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gram TE. Chemically reactive intermediates and pulmonary xenobiotic toxicity. Pharmacol Rev. 1997;49:297–341.

    CAS  PubMed  Google Scholar 

  5. Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opin Drug Saf. 2009;8:451–8.

    Article  CAS  PubMed  Google Scholar 

  6. Sikic BI. Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv. 1986;5(1):81.

    CAS  PubMed  Google Scholar 

  7. Aronchik J, Gefter W. Drug-induced pulmonary disorders. Semin Roentgenol. 1995;30:18–34.

    Article  Google Scholar 

  8. Kachel DL, Martin WJ 2nd. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther. 1994;268(1):42.

    CAS  PubMed  Google Scholar 

  9. Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use: two distinct patterns. Am J Respir Crit Care Med. 1996;154:1851–6.

    Article  CAS  PubMed  Google Scholar 

  10. Watanabe K, Sueishi K, Tanaka K, et al. Pulmonary alveolar proteinosis and disseminated atypical mycobacteriosis in a patient with busulfan lung. Acta Pathol Jpn. 1990;40:63–6.

    CAS  PubMed  Google Scholar 

  11. Aronin P, Mahaley M, Rudnick S. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med. 1980;303:183–8.

    Article  CAS  PubMed  Google Scholar 

  12. Schmitz N, Diehl V. Carmustine and the lungs. Lancet. 1997;349:1712–3.

    Article  CAS  PubMed  Google Scholar 

  13. Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging. 2003;18(4):231–6.

    Article  PubMed  Google Scholar 

  14. Andersson BS, Cogan BM, Keating MJ, et al. Subacute pulmonary failure complicating therapy with high dose Ara-C in acute leukemia. Cancer. 1985;56:2181–4.

    Article  CAS  PubMed  Google Scholar 

  15. Bredenfeld H, Franklin J, Nogova L, German Hodgkin’s Lymphoma Study Group, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin’s disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2004;22:2424–9.

    Article  CAS  PubMed  Google Scholar 

  16. Arrieta O, Gallardo-Rincón D, Villarreal-Garza C, Michel RM, Astorga-Ramos AM, Martínez-Barrera L, de la Garza J. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol. 2009;4(7):845–52.

    Article  PubMed  Google Scholar 

  17. Kuribayashi K, Voss S, Nishiuma S, Arakawa K, Nogi Y, Mikami K, Kudoh S. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study. Lung Cancer. 2012;75(3):353–9.

    Article  PubMed  Google Scholar 

  18. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, Joh T, Ohtsu A. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol. 2010;21(10):2005–10.

    Article  CAS  PubMed  Google Scholar 

  19. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer. 1986;58:1428–36.

    Article  CAS  PubMed  Google Scholar 

  20. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24.

    Article  CAS  PubMed  Google Scholar 

  21. Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer. 2001;85(9):1247.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006;129(4):1031.

    Article  CAS  PubMed  Google Scholar 

  23. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992;10:16–20.

    Article  CAS  PubMed  Google Scholar 

  24. Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer. 1998;34(1):71–5.

    Article  CAS  PubMed  Google Scholar 

  25. Yoh K, Kenmotsu H, Yamaguchi Y, Kubota K, Ohmatsu H, Goto K, Niho S, Ohe Y, Saijo N, Nishiwaki Y. Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol. 2010;5(9):1435–8.

    Article  PubMed  Google Scholar 

  26. Watkins J, Slade JH, Phan A, Eng C, Weissferdt A, Overman MJ. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer. 2011;10(3):198–202.

    CAS  PubMed  Google Scholar 

  27. Cardinale L, Asteggiano F, Moretti F, Torre F, Ulisciani S, Fava C, Rege-Cambrin G. Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome. World J Radiol. 2014;6(8):583–8.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan

    Yasuo Saijo

Authors
  1. Yasuo Saijo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuo Saijo .

Editor information

Editors and Affiliations

  1. First Department of Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan

    Masayuki Hanaoka

  2. Ibaraki Medical Center, Tokyo Medical University, Ibaraki, Japan

    Hiroyuki Nakamura

  3. Ibaraki Medical Center, Tokyo Medical University, Ibaraki, Japan

    Kazutetsu Aoshiba

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Saijo, Y. (2018). DLI Induced by Nonmolecular Target Antineoplastic Drugs: What Are the Characteristics of DLI in Nonmolecular Target Antineoplastic Drugs?. In: Hanaoka, M., Nakamura, H., Aoshiba, K. (eds) Drug-Induced Lung Injury. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-10-4466-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-4466-3_10

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-4465-6

  • Online ISBN: 978-981-10-4466-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation